This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

FDA Rejection of Titan's Probuphine Looks Like a Mugging

Stocks in this article: TTNP

SOUTH SAN FRANCISCO, Calif. ( TheStreet) -- The U.S. Food and Drug Administration came down hard on Titan Pharmaceuticals (TTNP), rejecting its Probuphine implantable therapy for opioid dependence and requesting a lot of new clinical data and other information before the company can resubmit.

Titan shares reacted as you'd expect -- down 73% to 44 cents in Wednesday trading.

Titan said it was "surprised and disappointed" in the FDA's Complete Response Letter but remains committed to addressing the agency concerns and getting Probuphine approved. The company and its partner Braeburn Pharmaceuticals intend to meet with the FDA to clarify exactly what's required.

But right now, the sting of FDA's rejection will take its toll on Titan's valuation given the uncertainty about the timing and cost of a Probuphine resubmission. The company has about $18 million in cash on hand, equivalent to 22 cents per share.

Investors were hoping FDA would approve Probuphine based on the generally positive recommendation favoring the new opioid dependence therapy made by an advisory panel in March. At worst, the FDA was expected to delay an approval decision so that the agency and Titan could complete work on a risk management plan to insure safe implantation and use Probuphine -- a series of small rods containing the drug buprenorphine that is implanted just under the skin of addicts and slowly releases the drug over six months.

Instead, FDA said it could not approve Probuphine until Titan comes back with new clinical data demonstrating the device's efficacy at additional dose levels, including the higher doses that more closely approximate blood levels of sublingual buprenorphine more commonly used today to treat opioid addicts.

This FDA request appears to come in direct response to concerns raised at the March FDA panel by an addiction expert who criticized Titan for not providing information to guide doctors on the number of Probuphine rods to implant in opioid addicts who were stabilized on oral buprenorphine.

The FDA also asked Titan to provide additional information on the training necessary to implant and remove Probuphine. Again, experts at the March advisory panel raised concerns about the level of training necessary to safely use Probuphine in patients.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs